Document is current
Any future updates will be listed below
-
Authors
Liu, Annie
Lowe, Melissa
Niedzwiecki, Donna
Rhodin, Kristen E.
Sharib, Jeremy
Wildman-Tobriner, Benjamin
Wong, Terence Z.
Kim, Charles Y.
Thacker, Julie
Mantyh, Christopher
Migaly, John
Lan, Billy Y.
Strickler, John H.
Hsu, S. David
Nussbaum, Daniel
Zani, Sabino
Uronis, Hope
Allen, Peter J.
Lidsky, Michael E.
- License Information
-
More Information
Article History
First Online: 2 January 2025
Disclosures
: John H. Strickler reports a consultant or advisory role for Abbvie, Agenus, Astellas, AstraZeneca, Bayer, Beigene, Daiichi-Sankyo, Eli Lilly, GSK, Johnson and Johnson, Jazz Pharmaceuticals, Merck, Natera, Pfizer, Roche/Genentech, Regeneron, Sanofi, Taiho, Takeda, and Xilio Therapeutics; holds stock options in Triumvira Immunologics; and has received research funding from or contracted research for Abbvie, Amgen, AStar D3, Bayer, Beigene, Curegenix, Daiichi-Sankyo, Eli Lilly, Erasca, GSK, Leap Therapeutics, Novartis, Pfizer, Quanta Therapeutics, Revolution Medicines, and Roche/ Genentech. Benjamin Wildman-Tobriner is a consultant for See-Mode Technologies. Annie Liu, Melissa Lowe, Donna Niedzwiecki, Kristen E. Rhodin, Jeremy Sharib, Terence Z. Wong, Charles Y. Kim, Julie Thacker, Christopher Mantyh, John Migaly, Billy Y. Lan, S. David Hsu, Daniel Nussbaum, Sabino Zani, Hope Uronis, Peter J. Allen, and Michael E. Lidsky have no disclosures to declare that may be relevant to the contents of this study.
